

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Angus McDougall Caithness
Date of last notice	4 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Banquo Consulting Pty Ltd - Mr Caithness is a director Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund - Mr Caithness is a director of the trustee and beneficiary
Date of change	15 April 2024

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p><u>Direct</u> 5,751,441 Ordinary shares 100,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 1,000,000 Retention Share Rights</p> <p><u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 5,548,000 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 32,000 Share Rights</p> <p><i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i> 150,000 Ordinary shares 150,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p>
Class	(a) Fully paid ordinary shares (b) Share rights
Number acquired	(a) 36,000 Fully paid ordinary shares
Number disposed	(b) 36,000 Share Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – issue of shares on conversion of share rights on 14 April 2024 according to their terms of issue

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<p><u>Direct</u> 5,751,441 Ordinary shares 100,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 1,000,000 Retention Share Rights</p> <p><u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 5,580,000 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights</p> <p><i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i> 150,000 Ordinary shares 150,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conversion of share rights to fully paid ordinary shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Fleta Jennifer Solomon
Date of last notice	4 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund - Ms Solomon is a director of the trustee and beneficiary
Date of change	15 April 2024
No. of securities held prior to change	<u>Direct</u> 21,587,216 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 1,000,000 Retention Rights 36,000 Share Rights <u>Indirect</u> 250,000 fully paid ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
Class	(a) Fully paid ordinary shares (b) Share rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	(a) 36,000 Fully paid ordinary shares
Number disposed	(b) 36,000 Share Rights
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil – issue of shares on conversion of share rights on 14 April 2024 according to their terms of issue
No. of securities held after change	<u>Direct</u> 21,623,216 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 1,000,000 Retention Rights <u>Indirect</u> 250,000 fully paid ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Conversion of share rights to fully paid ordinary shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
--	----

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.